Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Primary listing
Employees
109
Headquarters
Website
JANX Metrics
BasicAdvanced
$825M
-
-$1.83
2.88
-
Price and volume
Market cap
$825M
Beta
2.88
52-week high
$35.34
52-week low
$12.12
Average daily volume
1M
Financial strength
Current ratio
39.04
Quick ratio
38.924
Long term debt to equity
2.064
Total debt to equity
2.314
Profitability
EBITDA (TTM)
-155.638
Gross margin (TTM)
-1,158.96%
Net profit margin (TTM)
-1,136.25%
Operating margin (TTM)
-1,576.67%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-9.55%
Return on equity (TTM)
-11.48%
Valuation
Price to revenue (TTM)
84.027
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-10.09
Free cash flow yield (TTM)
-9.91%
Free cash flow per share (TTM)
-1.344
Growth
Revenue change (TTM)
-5.55%
Earnings per share change (TTM)
42.85%
3-year revenue growth (CAGR)
5.11%
3-year earnings per share growth (CAGR)
6.44%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
JANX News
AllArticlesVideos
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Business Wire·2 months ago
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Benzinga·2 months ago
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $825M as of March 26, 2026.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of March 26, 2026.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of March 26, 2026.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 2.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.